Neurocrine Biosciences logo

Neurocrine Biosciences

NBIX | NASDAQ
Chart Builder DCF Calculator
$165.42
-$1.98 (-1.18%)
At close: Nov 16, 2026, 4:00 PM ET
$163.74
-$1.68 (-1.02%)
After-hours: Nov 16, 2026, 7:56 PM ET
-1.18%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
84.1
Fundamentals Excellent
Market Sentiment Bullish
Moat Narrow
Sector Rank #10/1021 (Top 1%)

Key Statistics

Market Data

Market Cap $16.74B
1D Range
164.60 168.62
52W Range
123.10 185.50

Valuation (TTM)

PE 24.54
PB 4.32
EV/EBITDA 17.32

Valuation (NTM)

Forward PE 22.84
Forward PEG 0.53
Price Target $210.00
Loading financial charts...

Profile

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric condi...

Sector Healthcare
Industry Biotechnology
Employees 2,500
IPO Date May 23, 1996
Fiscal Year January - December

Latest News

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

14 hours ago · zacks.com

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
NBIX or GRDN: Which Is the Better Value Stock Right Now?

6 days ago · zacks.com

NBIX or GRDN: Which Is the Better Value Stock Right Now?
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

7 days ago · zacks.com

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy

8 days ago · zacks.com

All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
NBIX vs. GRDN: Which Stock Is the Better Value Option?

8 days ago · zacks.com

NBIX vs. GRDN: Which Stock Is the Better Value Option?
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?

8 days ago · zacks.com

Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

12 days ago · prnewswire.com

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences: Breaking Down A Solid Quarter

12 days ago · seekingalpha.com

Neurocrine Biosciences: Breaking Down A Solid Quarter
Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation

13 days ago · seekingalpha.com

Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free

13 days ago · seekingalpha.com

Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free

Earnings

Latest Earnings
Nov 2, 2026
EPS
$3.29
Beat +72.25%
REV
$1.12B
Beat +7.61%
Next Earnings
Feb 10, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
19
Consensus
Buy
Price Target
$210.00
Upside
+26.95%
Buy (16)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.